PRP vs Exosomes for Hair Loss: The Clinical Evidence
What does the clinical research show about PRP versus exosomes for hair regrowth?
The gap between these two treatments isn't really about biology, it's about how much evidence sits behind each one. Platelet-rich plasma has been studied in scalp hair loss since roughly 2006 and now carries dozens of randomized trials, while exosome therapy is about two decades behind that, with a human record built mostly on small open-label studies. If you're weighing them against each other, you're not choosing between two proven options, you're choosing between a modest proven effect and a promising unknown.
Platelet-rich plasma has moderate-quality randomized evidence of a real but modest benefit, commonly 15 to 30 additional hairs per square centimeter over placebo, while exosome therapy remains investigational with only two randomized controlled trials identified in the most recent systematic review.
How strong is the randomized controlled trial evidence for platelet-rich plasma in androgenetic alopecia?
Volume and quality aren't the same thing, and platelet-rich plasma has a lot more of the first. Reviews published since 2019 have pooled anywhere from nine trials to more than forty, but the studies inside them usually enroll 20 to 40 patients and close the books at three or six months. That's enough to show you a direction of benefit and nowhere near enough to tell you what your scalp looks like in year three.
- Trial size: Enrollment of 20 to 40 patients is the norm, with few reaching 60.
- Density effect: Pooled gains of roughly 15 to 30 hairs per square centimeter over placebo.
- Shaft diameter: Pooled analyses have not found a statistically significant gain here.
- Follow-up: Most trials stop at three or six months; data past two years is nearly absent.
Randomized trials of platelet-rich plasma typically enroll 20 to 40 patients and report pooled density gains of 15 to 30 hairs per square centimeter, with statistical heterogeneity often above 70 percent and almost no published follow-up beyond two years.
What does the published human evidence for exosome therapy in hair regrowth actually consist of?
Strip away the press coverage and the clinical record is thin. You'll find a lot of mechanism and very little proof, and those two are easy to confuse when a clinic is quoting you a price.
The published human evidence for exosome therapy in hair regrowth consists overwhelmingly of open-label single-arm studies with fewer than 40 participants, with double-blind placebo-controlled randomized trials numbering in the low single digits.
Which outcome measures do hair regrowth trials use, and how comparable are they across studies?
Comparability is where a lot of hair research quietly falls apart. Two studies can both report success while measuring completely different things: one counts hairs inside a tattooed square centimeter, another has a reviewer score a photograph, and a third just asks the patient how they feel about it. Those numbers don't stack on top of each other.
- Phototrichogram: Counts hairs and shaft width in the same marked square centimeter at every visit.
- Global photographic assessment: Blinded five or seven point scoring, sensitive to lighting, camera angle and styling.
- Patient-reported satisfaction: Correlates loosely with measured density and is the endpoint most vulnerable to expectation.
Hair count and shaft diameter move independently, so a treatment can thicken miniaturized hairs without producing a single new one, and phototrichogram counts, blinded global photographic scores and patient satisfaction are not interchangeable numbers.
How do the reported effect sizes for the two treatments compare when they are measured the same way?
Start with the trap, because almost every side-by-side claim falls into it. The platelet-rich plasma figures you see quoted are differences against a placebo arm, so the placebo response has already been subtracted out. The exosome figures are usually raw before-and-after changes with nothing subtracted, which makes them look larger for reasons that have nothing to do with the treatment.
| Basis of the number | Platelet-rich plasma | Exosome therapy |
|---|---|---|
| What the figure measures | Difference against a placebo arm | Raw before-and-after, no control |
| Typical reported change | 15 to 30 hairs per sq cm | Around 20 hairs per sq cm, single-arm |
| Confidence intervals | Narrower, pooled across many trials | Wide enough to include no difference |
| Other therapies reported | Sometimes balanced and disclosed | Rarely accounted for |
On the evidence as it stands, platelet-rich plasma is the defensible choice, because its 15 to 30 hairs per square centimeter is a placebo-controlled figure while exosome gains are uncontrolled before-and-after changes nobody has yet measured against a control.
What regulatory status applies to each treatment, and how does that shape the evidence base?
Regulation explains the shape of these two literatures better than any scientific difference does. Your own blood, spun and given back in a single visit, is handled as a blood product, so it never had to clear a premarket approval pathway and nobody can own the result. A donor-derived, manufactured vesicle product is a different legal object entirely, and that changes what a clinic is allowed to claim to you.
No exosome product currently holds regulatory approval for hair regrowth in the major markets, so any claim that an exosome treatment is proven to regrow hair goes further than the regulatory record supports.
Why do platelet-rich plasma trial results vary so widely from one study to the next?
The label describes a category, not a product, and that's the root of the whole problem. Two clinics can both hand you platelet-rich plasma and be giving you materially different material, injected in materially different ways, on materially different schedules.
- Spin protocol: Single-spin and double-spin runs concentrate platelets to very different degrees.
- Leukocyte content: Leukocyte-rich and leukocyte-poor preparations differ in inflammatory profile, and many trials omit which.
- Session structure: Three monthly sessions, four to six, or a six-month booster all appear in the literature.
- Delivery: Injection depth, volume per point and spacing from half a centimeter to two centimeters vary.
Platelet-rich plasma isn't a standardized product, since spin protocol, leukocyte content, activation method, injection depth and session schedule all differ between trials, which is why meta-analyses in this area keep reporting heterogeneity above 70 percent.
What safety data exists for each approach, and over what length of follow-up?
Short-term safety is the one place platelet-rich plasma's record is genuinely settled, and it's reassuring. Because the material is your own blood, there's no rejection risk and no donor disease to transmit, and what gets reported is local and temporary. Exosome risk sits somewhere different, less in the biology than in whether the vial in front of you was made under real quality control.
Reported adverse events for platelet-rich plasma are almost entirely local and transient, while the documented serious harm in exosome therapy has been bacterial infection traced to unapproved preparations, and no study has followed repeated exosome dosing into the scalp beyond roughly twelve months.
What would a well-designed head-to-head trial between the two need to look like?
Design it backwards from the question you'd actually ask, which isn't whether either treatment beats nothing. It's whether one beats the other by enough to justify the difference in price, and nothing published in either field is built to answer that.
- Size it honestly: Detecting a difference of about 10 hairs per square centimeter needs roughly 150 to 250 patients per arm.
- Blind it with a double dummy: Every participant gets a blood draw and an injection of identical appearance, with unblinded staff kept out of assessment.
- Run it twelve months: Assess at three, six, nine and twelve, since early shedding and the needle's own effect contaminate the first window.
- Prespecify the endpoints: Phototrichogram count in a tattooed area as primary, with shaft diameter, blinded photo scoring and patient-reported outcome registered as secondary.
- Publish both protocols in full: Platelet concentration, leukocyte status and activation for one arm, and source tissue, isolation method and particle count for the other.
A trial capable of separating these two treatments needs roughly 150 to 250 patients per arm, a double-dummy blind, at least twelve months of follow-up with assessments at three, six, nine and twelve months, and a prespecified phototrichogram endpoint registered before the first patient enrolls.
How should the price of each treatment be weighed against the strength of its evidence?
Price and proof run in opposite directions here, which is the uncomfortable part of this decision. The cheapest options carry the strongest evidence, thousands of patients studied over years, while the most expensive carries the weakest. That doesn't make the expensive path wrong for you, but it does mean you're paying a premium for potential rather than for a demonstrated advantage.
| Cost and evidence | Platelet-rich plasma | Exosome therapy |
|---|---|---|
| Per session | 500 to 1,200 dollars | 1,000 to 3,500 dollars |
| First year | Roughly 1,500 to 4,500 dollars | Higher, often sold as an add-on |
| Maintenance | Every four to six months, indefinitely | Undefined, no durability data |
| Evidence behind it | Moderate, placebo-controlled | Early and largely uncontrolled |
A platelet-rich plasma session commonly runs 500 to 1,200 dollars against 1,000 to 3,500 dollars for exosome therapy, and because neither addresses the hormonal driver of pattern hair loss, the gains fade over six to twelve months once treatment stops, making either one an indefinite course rather than a one-time purchase.
